Pulmonary Hypertension Inspiratory Training
Part of paid clinical trials in Tucson, Arizona.
- Sponsor
- University of Arizona
- Study ID
- NCT06931886
- Status
- Enrolling By Invitation
Conditions
- Pulmonary Hypertension
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Inspiratory Muscle Strength Training — OTHERParticipants will be asked to inhale against a resistance. This resistance will be set to \~55% of their maximal inspiratory ability. Participants will complete 5 sets of 6 breaths (30 total) a day for 5 days a week for 6 weeks.
Study Details
This study is examining the effects of six weeks of inspiratory muscle strength training (IMST) on outcomes related to pulmonary hypertension. This study leverages previous cardiopulmonary exercise test (CPET) results and a pre-existing upcoming CPET to examine the effects of IMST on cardiopulmonary pressures and exercise tolerance and ability.
Key Dates
- Start date
- Oct 25, 2025
- Status verified
- Jul 2025
- Primary completion
- May 31, 2026
- Completion
- Oct 31, 2026
Study Design
- Enrollment
- 4 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- SUPPORTIVE_CARE
Arms
- Experimental: Inspiratory Muscle Strength TrainingThis group will perform inspiratory muscle strength training (\~5 min/day) for 5 days a week for 6 weeks.
Primary Outcome Measure
Pulmonary arterial pressure [ Time Frame: The data will be obtained from previous medical records of patient visits occurring up to 8 months prior to enrollment and at the end of treatment at 6 weeks post enrollment. . ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Arizona | Tucson | Arizona | 85711 | - |
Find similar trials in Tucson, AZ
By research site
Related Studies
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPHASE3 · Enrolling By Invitation · United Therapeutics · Phoenix, Arizona
- Pulmonary Hypertension Association RegistryRecruiting · Pulmonary Hypertension Association, Inc. · Phoenix, Arizona
- LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFPHASE3 · Recruiting · Tenax Therapeutics, Inc. · Tucson, Arizona
- DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)Recruiting · United Therapeutics · Birmingham, Alabama